|

Bortezomib (Velcade®) Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Also known as: Velcade, bortezomib injection (generic)

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Intergroupe Francophone du Myelome1
  • Eastern Cooperative Oncology Group1

Indications

  • Cancer2
  • Multiple Myeloma, Newly Diagnosed1
  • Myeloma, Multiple1

Other1 trial

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Phase 3

Anchorage, Alaska1 trial

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Alaska Oncology and Hematology LLC

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.